UPDATED: June 26, 2021 14:18 IST
Dr Sangeeta Talwar at work at the Maulana Azad Institute of Dental Sciences; Photo by Yasir Iqbal
1. Maulana Azad Institute of Dental Sciences, New Delhi
1. Maulana Azad Institute of Dental Sciences, New Delhi
Guru Speak | Dr Sangeeta Talwar
Director, Maulana Azad Institute of Dental Sciences, New Delhi Dentistry requires students to have exposure to patients the practical aspect is crucial in our curriculum. Last year, after establishing Covid protocols and SOPs, we restarted our clinical programme in November, though it was halted when the second wave hit this March. But even at the peak of both waves, the residents (postgraduate students) and faculty continued to perform dental surgeries; the hospital was not shut for even a day. The entire institute has learned to conduct RT-PCR tests, and we hold refresher training for Covid diagnosis at regular intervals. This has helped us stay safe. For the undergraduate students, post the second wave,
Support for chancellor s decision on RGUHS VC post
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Made in Coupar Angus: NFL coach Jock Sutherland remains a hero in Pittsburgh
eveningtelegraph.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eveningtelegraph.co.uk Daily Mail and Mail on Sunday newspapers.
Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics
Biomarkers are important determinants of appropriate and effective therapeutic approaches for various diseases including cancer. There is ample evidence pointing toward the significance of immune check point inhibitors (ICI) against cancer, and they showed promising clinical benefits to a specific group of patients with colorectal cancer (CRC). Several reports demonstrated the efficacy of biomarkers such as programmed death-1 protein ligand (PD-L1), density of tumor-infiltrating lymphocytes (TILs), and tumor mutational burden (TMB), to determine the patient responsiveness for the efficient use of ICIs as therapeutics against cancer.
A high level of TMB (TMB-H), which reflects elevated total number of non-synonymous somatic mutations per coding area of a tumor genome and normally derived from gene panel testing, is recognized as a promising biomarker for the ICI therapies of various